home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

The Use and Mis-use of FMEA in Medical Device Risk Management

 
  March 07, 2011  
     
 


GlobalCompliancePanel, Online Training Webinar
2011-04-06


Overview: The purpose of FMEA is to affect the design and the most practical time to do this is when competing designs are being considered, not after choices have been made, contracts signed, and prototypes being built and tested.

Of course, there are other reasons for performing a FMEA. FDA requires risk assessment (hazard analysis) but a FMEA conducted late in the product development process is largely a documentation exercise - rarely does this FMEA affect the design. Emphasis is placed on enhancing the power and benefits of FMEA for your organization by avoiding common pitfalls and concentrating efforts toward the real value of the FMEA process.

Areas Covered in the Session:
  • What is an FMEA
    • What are the components of an FMEA?
  • How should I use FMEA in performing risk management?
  • What are the problems with FMEA in risk management?
  • How is an FMEA conducted
    • What and who are needed
    • Identifying significant risks
    • Development of mitigating actions
  • Discussion of specific elements of an FMEA
  • Follow up activities
    • Post action risk
  • Advantages
  • Disadvantages and pitfalls
  • How should delectability be used in FMEA?
  • Is there a role for RPN (Risk Priority Number)?
  • Are there other tools to use in conjunction with FMEA?
  • Are there FMEA applications in production as well as design?
Who Will Benefit: This webinar will inform personnel at medical device companies on how to properly use Failure Modes and Effects Analysis (FMEA) in performing Risk Management.
  • Product Design Teams and personnel assigned to use FMEA at medical device companies
  • Quality Managers
  • Regulatory and Compliance Personnel
  • Personnel Responsible for Verification and Validation Activities
  • Quality System Auditors
 
 
Organized by: GlobalCompliancePanel
Invited Speakers: Nancy, is the Director of Quality & Regulatory Affairs, Healthcare responsible for global coordination of Celestica's Healthcare Quality, Regulatory and FDA compliance. Nancy is Quality and Regulatory expert with fifteen years experience in regulatory affairs, quality systems, compliance, clinical quality, validation, auditing, quality control, data management systems, post market surveillance, supplier management and regulatory compliance in the areas of bio/pharmaceuticals, medical devices and combination products. Nancy has contributed to the success of both venture and public companies, establishing a track record of successfully achieving timely global regulatory approvals, initiating and effectively managing preclinical and clinical investigations and developing and maintaining effective and compliant quality systems in various healthcare sectors.
 
Deadline for Abstracts: 2011-04-06
 
Registration: Price List:
Live : $245.00
Corporate live : $995.00
Recorded : $295.00
E-mail: webinars@GlobalCompliancePanel.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.